Objectives: To construct a model to predict long-term bleeding events following percutaneous coronary intervention (PCI). Background: Treatment with dual antiplatelet therapy following PCI involves balancing the benefits of preventing ischemic events with the risks of bleeding. There are no models to predict long-term bleeding events after PCI. Methods: We analyzed 1-year bleeding outcomes from 3,128 PCI procedures in the Patient Risk Information Services Manager (PRISM) observational study. Patientreported bleeding events were categorized according to Bleeding Academic Research Consortium (BARC) definitions. Logistic regression analysis was used to develop a model predicting BARC ! 1 bleeding. Results: BARC 0, 1, 2 or 3 bleeding was observed in 574 (18.4%); 2382 (76.2%); 114 (3.6%); and 58 (1.8%) patients, respectively. Compared to patients who had no bleeding, patients with BARC ! 1 bleeding were more often female (30 vs. 23%), Caucasian (94 vs. 83%), had a higher incidence of drug eluting stent (DES) implantation (83 vs. 76%) and warfarin therapy (7.4 vs. 3.9%), and a lower incidence of diabetes (31 vs. 45%; P-value <0.01 for all comparisons). A 27-variable model had moderate discrimination (c-statistic of 0.674), and good calibration, as did a parsimonious model with 10 variables (c-statistic 5 0.667). This model performed well in predicting BARC ! 2 bleeding events as well (c-statistic 5 0.653). Conclusions: Bleeding is common in the first year after PCI, and can be predicted by pre-procedural patient characteristics and use of DES. Objective estimates of bleeding risk may help support shared decision-making with respect to stent selection and duration of antiplatelet therapy following PCI. V C 2016 Wiley Periodicals, Inc.
INTRODUCTION
Bleeding is a major complication in patients undergoing percutaneous coronary intervention (PCI). To lay the foundation for quantifying the severity of bleeding, the Bleeding Academic Research Consortium (BARC) created a standardized bleeding definition [1] . While several risk models have been developed to predict peri-procedural bleeding [2, 3] , post-discharge bleeding after PCI is also common, but has been inadequately Additional Supporting Information may be found in the online version of this article.
studied. The majority of prior studies have focused on "major bleeding" complications after PCI; however, many patients report "minor" or "nuisance" (BARC 1) bleeding events and patients with BARC 1 bleeding have worse quality of life and higher readmission rates than those without bleeding, underscoring the clinical importance of these more minor bleeds [4, 5] . Understanding patients' bleeding risk in the year after PCI can be extremely helpful in selecting drug eluting stents (DES) or bare metal stents (BMS) at the time of PCI and determining the optimal duration of dual antiplatelet therapy (DAPT) following PCI. While DES use markedly reduces the risk of a repeat PCI procedure [6] , it also necessitates prolonged DAPT to reduce the risk of stent thrombosis. DAPT increases patients' bleeding risk [5] , and is typically recommended for 4 weeks [7] in non-acute coronary syndrome patients treated with BMS, and for at least 12 months in patients receiving DES [8] . While risk models to predict restenosis have been developed to more explicitly describe the benefits of DES [9] , models to predict bleeding have largely focused on short-term, rather than long-term bleeding events. There is therefore an unmet need for a risk model to predict long-term bleeding events following PCI, which can address an important gap in clinical care by enabling doctors and patients to compare the benefits of DES in reducing restenosis against the risks of bleeding events related to prolonged DAPT after discharge [10] . To address this gap in knowledge, we developed a model to predict the risks of long-term bleeding events after PCI, including overt bleeding requiring medical care (BARC 2) as well as less severe (BARC 1) bleeding events [1] .
MATERIALS AND METHODS
Our study participants were derived from the Patient Risk Information Services Manager (PRISM) prospective observational study [11, 12] . Details of the PRISM study have been described previously [13] . Briefly, 3,299 consecutive patients undergoing PCI at 10 U.S. hospitals between 2009 and 2011 were approached to participate in the PRISM study. Consenting patients were enrolled within 24 hours of their index procedure. Institutional Research Board approval was obtained from all participating sites, and all patients provided informed consent for baseline and follow-up assessments. As part of the study, patients were asked to provide follow-up telephone interviews at 1, 6, and 12 months after discharge. In this analysis, we included all surviving patients who had follow-up data available.
Using a method we had previously used to assess bleeding events after myocardial infarction [5] , at each follow-up interview, we asked patients two questions pertaining to bleeding. The first asked whether they had experienced "no bleed", "easy bruising", "easy bleeding", "occasional nose or gum bleed" or "serious bleeding" since their last interview. If any bleeding outcomes were reported, a follow up question was asked to characterize the treatment for their bruising or bleeding. Choices included "didn't tell any doctor", "told doctor, but no treatment", "doctor stopped a medicine or switched to another medicine", "treated with transfusion" or "treated by hospitalization". Patient responses were re-classified according to the BARC classification [1] in which bleeding events are graded from 0-5, as follows: BARC 0 indicates no bleed or bruising, BARC 1 represents bleeding (including bruising) that does not require the patient to seek medical care, BARC 2 represents overt bleeding events requiring medical care (but not BARC 3 events), BARC 3 indicates bleeding that required blood transfusion or hospitalization, BARC 4 indicates coronary artery bypass grafting-related bleeding, and BARC 5 indicates fatal bleeding. The PRISM study excluded patients undergoing coronary artery bypass grafting; therefore, only BARC 0, 1, 2, and 3 categories were evaluated in this analysis.
We categorized patients according to the most severe grade of BARC bleeding experienced within the 12 months after their PCI. Baseline characteristics were compared between these groups for descriptive analyses. Continuous variables were compared using Student's t-test and categorical variables using the chisquare or Fisher's exact test. A multivariable logistic regression model was then constructed to identify variables associated with BARC !1 bleeding through 12-month follow-up The following covariates were selected, a priori, for inclusion in the model based on previous bleeding models and clinical judgment: age, gender, ethnicity, high-school education, insurance status, smoking status, body mass index (BMI), peripheral arterial disease, diabetes mellitus, chronic kidney disease, prior myocardial infarction, prior PCI, congestive heart failure, hypertension, prior cerebrovascular accident, dyslipidemia, chronic lung disease, glomerular filtration rate (GFR), treatment with DES, hemoglobin, platelet count, index presentation with ST segment elevation myocardial infarction (STEMI), PCI status (elective/planned vs. urgent vs. emergent), access site (femoral vs. other), cardiac arrest, prior history of bleeding, and warfarin use at the time of hospital admission. Collinearity was assessed by evaluating the condition index, in which a value of 30 or higher suggests significant multicollinearity [14] .
To create a more parsimonious set of variables for the final model, we used Harrell's backward selection strategy [15] . The contribution of each covariate in the multivariable model was ranked by F-value, and variables with the smallest contribution to the model were sequentially eliminated until further variable elimination led to a >10% loss in model prediction, as compared with the initial model. A second analysis was performed to predict the performance of the final model to predict BARC !2 bleeding events. The discriminative power of both the full and reduced models was assessed with the c-statistic. Calibration of both models was assessed by plotting observed vs. predicted probabilities within deciles of predicted risk, and the regression line was compared against the line of unity (intercept ¼ 0 and slope ¼ 1). Internal validation of the model was evaluated by performing 100 bootstrapped samples to derive an optimism-corrected c-statistic. Finally, a simplified scoring tool was developed from the final reduced model by rescaling and rounding the beta weights to integer point values (continuous predictors were categorized to facilitate scoring).
Among the 3128 patients with at least one follow-up reported, 330 (11%) were missing the bleeding outcome at 1 year, of whom 124 (38%) had not reported a bleed at previous follow-up time points. Among the entire population, 82% had no missing data; 13.6% had one variable missing; and 4.4% had >1 variables missing at baseline. Platelet count was the most commonly missing variable (5.8% patients). To address loss to follow-up between 6 and 12 months and to address the potential bias, we performed a sensitivity analysis in which we partitioned the outcome into two variables: bleeding between 0 and 6 months and bleeding between 6 and12 months. We then used multiple imputation methods to estimate the missing 6-12 month data using IVEware (Imputation and Variance Estimation Software; University of Michigan's Survey Research Center, Institute for Social Research, Ann Arbor, MI). We used sequential regression imputation, incorporating all predictor variables and all available outcome data, to construct 50 imputed data sets. After imputing, we reaggregated the 0-6 months bleeding and 6-12 months bleeding variables into a single 0-12 month outcome. The bleeding risk model was refit on each data set, and the resulting model estimates were pooled across data sets to incorporate uncertainty due to missing data. All analyses were conducted using SAS v9.3 (SAS Institute, Cary, NC), and statistical significance was determined by a 2-sided P-value of <0.05.
RESULTS
Among 3,299 patients who were enrolled in the PRISM study, 3,128 (95%) patients had follow-up bleeding data available at 1, 6 or 12 months and were included in this analysis. Over the 12 months following PCI, 574 patients (18.4%) reported no bleeding, 2,382 (76.2%) reported BARC 1 bleeding, 114 (3.6%) reported BARC 2 bleeding, and 58 (1.8%) reported BARC 3 bleeding. The incidence of BARC !1 bleeding was 58.8% at 1 month, 71.8% between 1 and 6 months, and 68.7% between 6 months and 1 year. Of those patients who reported a bleed at 1 month and had a follow-up time point (n ¼ 735), 682 (93%) reported additional subsequent bleeding between 1 month and 1 year.
Among patients with BARC 1 bleeding, 602 (25.2%) reported easy bruising as the only event during the 12 months of follow-up. Compared with patients who reported no bleeding, those with BARC !1 bleeding were more likely to be female, of Caucasian race, to have chronic lung disease, to have undergone elective/planned PCI, to be on oral anticoagulation with warfarin or to have undergone DES implantation (Table I) (Table II) , demonstrated similar discrimination (c-statistic ¼ 0.667; optimism-corrected c-index ¼ 0.647) and good calibration, with an intercept and slope not statistically different from 0 and 1, respectively (both P ¼ 0.54), and a correlation of 0.98 between deciles of predicted and observed bleeding (Fig. 1) . The simplified scoring tool for predicting BARC ! 1 bleeding after PCI is depicted in Fig. 2 . Patients in the lowest category of predicted risk (risk score < 40) reported a 12-month BARC !1 bleeding rate of 53.5% as compared with 91.2% of the patients in the highest category of predicted risk (risk score ! 70).
The final model also performed well in predicting BARC 2 or greater bleeding events (Table II) . Important predictors of BARC 2 or greater bleeds included Caucasian race (OR 2.53, 95% CI 1.10-5.83) and warfarin use upon arrival (OR 3.62 95% CI 2.37-5.55). There were important differences in predictive value of several variables in predicting BARC 1 vs. BARC 2 or greater bleeding events (Table II) . While DES use was associated with higher odds of BARC ! 1 bleeding (OR1.54, 95% CI 1.23-1.94; P < 0.001), it was associated with a lower risk of BARC ! 2 bleeding (OR 0.65 95% CI 0.45-0.92). The discrimination of the model predicting BARC ! 2 bleed was also slightly lower at 0.653, however the calibration was similar with a correlation of 0.98 between deciles of predicted and observed bleeding, and a slope and intercept not statistically different from the line of unity (P ¼ 0.87 for intercept and P ¼ 0.85 for slope). After partitioning the data at 6 months and using multiple imputations, we developed a final parsimonious model, which was very similar to our original model (Supporting Information Appendix 2) with the only difference being that age and body mass index were no longer independently associated with bleeding. The effect sizes for the remaining variables were similar in strength to the variables included in the primary analysis.
DISCUSSION
While prior research efforts have largely focused on peri-procedural bleeding complications [2, 3] , this is the first model that has been developed to predict longterm bleeding risk in patients undergoing PCI. We found that patient-reported bleeding is exceedingly common after PCI, and that it can be predicted by readily available clinical factors at the time of PCI. In addition, this study is unique in that we characterized the risk of "minor" bleeding and bruising, which impacts patients' quality of life [4, 5] . Understanding patients' risk for bleeding can be very helpful in setting patients' expectations for the outcomes after PCI, understanding their tolerance for prolonged DAPT, and in selecting between DES and BMS.
While the use of DES during PCI has been a major advance in the field of interventional cardiology, with a marked reduction in restenosis and the need for repeat revascularization procedures as compared with use of BMS [6] , the use of DES also necessitates prolonged DAPT to reduce the risk of stent thrombosis, which in turn increases bleeding risk [8] . Long-term bleeding after PCI has been associated with an increased rate of all-cause mortality comparable in effect to the rate of mortality following a recurrent myocardial infarction [16, 17] . Two recent studies have demonstrated a tradeoff between the safety and efficacy of long-term DAPT after PCI. Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) study [18] evaluated long-term DAPT with aspirin and ticagrelor beyond 1 year following PCI, and demonstrated a lower incidence of cardiovascular death, myocardial infarction, or stroke, but an increased risk of bleeding with prolonged DAPT as compared to placebo. Similarly, the DAPT study [19] reported a reduction in ischemic events with DAPT beyond 1 year following PCI, but increased bleeding events as compared with placebo therapy.
In our simplified 10-item model, the use of DES increased the odds of bleeding over the year after PCI by 54%, presumably secondary to prolonged DAPT therapy. Thus, the findings from this study are actionable, in that they may be used to predict the risk of long-term bleeding in patients undergoing PCI so that the choice between BMS and DES and their associated impact on the duration of DAPT can be individualized. Coupling prior models of predicting restenosis [9] with this bleeding model could further support evidencebased shared medical decision-making and personalized care. For example, patients with stable coronary artery disease (CAD) who are at low risk of restenosis with BMS and a high risk of long-term bleeding may prefer to receive BMS at the time of PCI and shorterterm DAPT. BARC ! 2 bleeding was much less common that BARC 1 bleeding in our study. In comparing the predictive values of variables predicting BARC ! 1 and BARC ! 2 bleeding events, we found important differences. The main predictor of BARC ! 2 bleeding appears to be Caucasian race and warfarin use upon arrival. Interestingly while DES use was associated with more BARC ! 1 bleeding, it was associated with lower rates of BARC ! 2 bleeding events, a finding that, to the best of our knowledge, has not been previously reported. This may be partially explained by lower DES use amongst patients already on warfarin therapy or other, non-quantified aspects of clinical judgment, when clinicians may prefer to use BMS. However, BARC 2 bleeding events by definition consist of events which lead to changes in medical care or therapy. We speculate that while physicians may consider it reasonable to discontinue antiplatelet therapy after 1 month in patients treated with bare metal stents who have bleeding concerns, they are less likely to discontinue antiplatelet therapy in patients treated with DES until they have completed 12 months of DAPT. Thus, patients treated with DES who have bleeding that does not require hospitalization or transfusion may be continued on DAPT and these bleeding events may be less likely to be classified as BARC 2 events. However, this potential explanation requires further study.
Several predictors identified in our model are also predictors of peri-procedural bleeding at the time of PCI, including age, female sex, and chronic kidney disease [2, 3] . However, we also identified several novel predictors of long-term bleeding, including use of DES, which was associated with 54% higher odds of minor bleeding; diabetes, which was associated with 44% lower odds of bleeding events; and lower platelet count, chronic lung disease, and warfarin use on arrival, all of which increased patients' risks for bleeding over the year after PCI. We believe that the association of DES with minor bleeding is attributable to the longer duration of DAPT therapy typically prescribed after DES implantation [5] . We hypothesize that the association between diabetes mellitus and lower rates of bleeding may be related to increased platelet reactivity 
